$3.30
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
Rocket Pharmaceuticals Closes $180 Million Sale of Pediatric Priority Review Voucher
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Overview
52-week range
$2.40
$5.45
30% of range
Avg surprise (last 3)
-0.3%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
258%
EM ±59.1% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.42 | $-0.41 | -2.4% | +25.0% | -4.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.45 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.59 | $-0.57 | -3.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.56 | $-0.59 | +5.1% | — | +5.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.71 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.74 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.66 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.75 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.82 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | $0.28 | -$0.59 | +147.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-49M | — | $-52M | $-71M | $-64M | — | $-69M | $-74M |
| Net income | $-48M | — | $-50M | $-69M | $-61M | — | $-67M | $-70M |
| EPS (diluted) | $-0.42 | — | $-0.45 | $-0.62 | $-0.56 | — | $-0.71 | $-0.74 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $50M | $78M | $76M | $33M | $50M | $164M | $66M | $39M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $150M | $193M | $228M | $277M | $324M | $378M | $242M | $293M |
| Total assets | $285M | $330M | $368M | $421M | $471M | $528M | $394M | $446M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $47M | $53M | $54M | $67M | $59M | $64M | $64M | $62M |
| Total equity | $238M | $277M | $314M | $354M | $412M | $463M | $330M | $385M |